<DOC>
	<DOC>NCT02558790</DOC>
	<brief_summary>This study is a 12-week, open-label pilot study to test the effects of MMFS-201-301 on cognition and function in adults with ADHD. Subjects may enter the trial on a stable dose of medication for ADHD, and MMFS-201-301 will be given. Subjects who do not enter on a stable dose of ADHD medication will receive MMFS-201-301 alone.</brief_summary>
	<brief_title>Magnesium L-Threonate Supplementation in ADHD</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>Male or female adults ages 1855 years of age A diagnosis of childhoodonset Attention Deficit/Hyperactivity Disorder (ADHD), meeting the Diagnostic and Statistical Manual, Fifth Edition (DSMV) criteria for ADHD in adulthood, including at least 5 current symptoms of inattentive or impulsivehyperactive traits, and childhood onset by age 12, defined as two symptoms of inattentive or of impulsive/hyperactive traits by the age of 12 A score of 20 or more on the Adult ADHD Investigator Symptom Report Scale (AISRS), and, for those individuals stably treated with stimulants, a Clinical Global Impression ADHD (CGIADHD) severity score of no greater than 4 ("moderately ill") Subjects on a stable dose of stimulant medication must be treated on the same dose for at least 1 month prior to study entry A history of intolerance to magnesium supplementation, the ingredients in MgT201 Pregnant or nursing females A known unstable medical illness including hepatic, renal, gastroenterological, respiratory, cardiovascular (including hypertension â‰¥ 140/90 mmHg at screening), endocrinologic (e.g. thyroid), neurologic (e.g. seizure), immunologic, hematologic, or psychiatric (other than ADHD) disorder); individuals with kidney dysfunction will be excluded, as dysfunctional kidneys may have difficulty clearing the magnesium from the body (which can result in dangerously high magnesium levels); individuals with heart block will be excluded from the study Any medical condition that the Principal Investigator believes will be exacerbated by study participation A history of cancer (except localized skin cancer without metastases or in situ cervical cancer) within 5 years prior to screening A known history of narrowangle glaucoma Current (within 3 months) DSMV criteria for abuse or dependence with any psychoactive substance other than nicotine Intelligence Quotient less than 80 Multiple adverse drug reactions Any other concomitant medication with primarily central nervous system activity as specified in the study protocol Current use of a monoamineoxidase inhibitor (MAOI) or use within the past two weeks Current use of antibiotics, as the study agent may reduce the absorption of antibiotics Subjects may not take any of the following substances for at least 7 days prior to baseline and throughout the study: Calcium channel blockers; any psychoactive medications; any medications known to interact with magnesium; supplemental magnesium or any magnesiumcontaining products; all dietary or herbal supplements or products including those purported to improve memory, improve sleep, or decrease stress. Investigator and his/her immediate family; defined as the investigator's spouse, parent, child, grandparent, or grandchild</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Attention Deficit/Hyperactivity Disorder</keyword>
	<keyword>ADHD</keyword>
	<keyword>Attention Deficit Disorder</keyword>
	<keyword>ADD</keyword>
	<keyword>Magnesium</keyword>
</DOC>